scholarly journals Epidemiology and diagnosis of inflammatory bowel diseases

2021 ◽  
Vol 64 (9) ◽  
pp. 579-587
Author(s):  
Kang-Moon Lee
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Public Awareness ◽  
Intestinal Tuberculosis ◽  
Diagnostic Delay ◽  
Perianal Fistula ◽  
Diagnostic Tools ◽  
Male Predominance ◽  
The Past ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Background: Over the past three decades, inflammatory bowel diseases (IBD) have been rapidly increasing in the African, South American, and Asian countries, including Korea. However, in Korea, the public awareness of IBD remains low, and diagnostic delay is not uncommon due to the physicians' lack of clinical experience. It is essential to understand the trends and regional differences in the epidemiology of IBD for proper diagnosis and treatment.Current Concepts: Although lower than those of the West, the prevalence and incidence of IBD in Korea rank among the highest in Asia and are steadily increasing. In the past 10 years, the prevalence of IBD has almost doubled, while its incidence has decreased gradually. As compared to Western IBD patients, Korean patients have higher proportion of proctitis in ulcerative colitis, male predominance, more ileocolonic involvement, and higher incidence of perianal fistula in Crohn disease. There is no single gold standard for the diagnosis of IBD. Thus, diagnosis can be made by clinical evaluation, including a detailed history taking, physical examination, and a combination of endoscopic, radiologic, laboratory, and histologic findings.Discussion and Conclusion: Population-based studies have revealed the current trends and characteristics of the epidemiology of IBD in Korea. Continued education and development of diagnostic tools will help clinicians to diagnose IBD accurately and differentiate it from other diseases such as intestinal tuberculosis.

scholarly journals Characterization of stable RNAs from the resected intestinal tissues of individuals with either Crohn's disease or ulcerative colitis

1997 ◽  
Vol 75 (6) ◽  
pp. 789-794 ◽  
Author(s):  
Guylaine Roy ◽  
Stéphane Mercure ◽  
Frédéric Beuvon ◽  
Jean-Pierre Perreault
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Ribosomal Rna ◽  
Inflammatory Bowel Diseases ◽  
Molecular Diagnostic ◽  
Diagnostic Tools ◽  
Circular Rnas ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Circular RNAs reminiscent of viroids and the human hepatitis delta virus have been proposed as possible nonconventional pathogens responsible for Crohn's disease and ulcerative colitis, two inflammatory bowel diseases. Consequently, RNA was extracted from various areas of intestinal tissues from individuals with either Crohn's disease or ulcerative colitis as well as several appropriate control diseases, and analyzed by two-dimensional gel electrophoresis. No circular viroid-like RNAs (<1500 nucleotides) were detected, confirming a previous report that was limited to the investigation of small RNAs (<300 nucleotides). However, three small, unusually stable, linear RNAs were shown to be associated to both Crohn's disease and ulcerative colitis tissues: a specific 28S ribosomal RNA cleavage product characterized previously; a 5.8S ribosomal RNA conformer; and a fragment homologous to transcripts from DNA CpG islands. The two last RNAs were detected prior to visible morphological tissue alterations, suggesting that they are produced early during the inflammation and that they have value as molecular diagnostic tools for the inflammatory bowel diseases. The potential cellular mechanisms producing these RNAs and their involvement in inflammatory bowel disease are discussed. Key words: ribosomal RNA, inflammatory bowel diseases, human intestine, inflammation, viroids.

scholarly journals P163 Changes in diagnostic delay in inflammatory bowel diseases over the years: a retrospective single-centre analysis

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S220-S220
Author(s):  
M Di Ruscio ◽  
F Vernia ◽  
A Variola ◽  
G Lunardi ◽  
S Resimini ◽  
...  
Keyword(s):  
Median Time ◽  
Inflammatory Bowel Diseases ◽  
Biological Treatment ◽  
Diagnostic Delay ◽  
Delayed Diagnosis ◽  
Age Related ◽  
Time To Diagnosis ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
The Difference

Abstract Background Delayed diagnosis is common in inflammatory bowel diseases (IBD) and has been reported to be longer for patients with Crohn’s disease (CD) than for those with ulcerative colitis (UC). Aims of study were to assess the median time to diagnosis in IBD patients, to examine whether diagnostic delay (DD) has improved over the years and its impact on biological treatment and need for surgery. Methods A retrospective monocentric study including IBD patients living in the area of Verona (Italy), diagnosed up to 2019 and followed-up for at least 6 months at IRCCS Sacro Cuore—Don Calabria, Negrar, was carried out. DD was defined as the period (months) from symptoms onset to histological diagnosis of IBD and reported as &lt;6 months, 6–12 months and &gt;12 months. Results Six-hundred-six patients (255 CD; 351 UC; 308 males; 298 females) were enrolled. Median DD was 10 (IQR 2–12), 6 (IQR 1–12) and 2 (IQR 1–7) months &lt;2000, between 2001–2010, and &gt;2010, respectively. Median time to diagnosis was not significantly longer in CD than in UC patients (4 vs. 3 months; IQR 1- 12). No sex- or age-related differences in DD were observed. Using the Mann–Whitney test, DD was longer in patients diagnosed &lt;2000 and between 2001–2010, than in those diagnosed &gt;2010 (p = 0.0000 and p = 0.0004). Comparing DD &lt;2000 and &gt;2010, the statistical difference was reported for UC (p = 0.0000) but not for CD (p = 0.2756). Considering the use of biologics over the years, patients diagnosed between 2000–2010, and &gt;2010 were compared (194 CD and 333 UC), reporting a significant increase in their use both for CD (30 vs. 60; p = 0.0008) and UC (28 vs. 43; p = 0.0000). DD did not influence the need for biological treatment in both diseases (p = 0.987 for CD; p = 0.433 for UC). Considering a DD &lt;6, 6–12, and &gt;12 percentages of patients needing biologics were respectively 53.4%, 63.6% and 56.5% for CD and 28.5%, 34.1% and 26.3% for UC. Seventy-two CD and 27 UC patients needed surgery. Analyzing the time to surgery, DD did not influence the rate of resections in CD (p = 0.6559), as well as in UC (p = 0.2792). Conclusion In our cohort, DD has significantly decreased over the last years, more for UC than CD patients. This is probably related to the increased awareness of patients on disease and of general practitioners in sending them to the specialist. Considering the published literature, UC and CD did not differ in DD; moreover age at diagnosis did not affect DD in our patients. DD did not influence the need for biological treatment or surgery rates in both diseases. These results are probably related to the difference in disease extension and severity among the patients enrolled. An analysis on targeted patients at higher risk for bowel damage is presently under way.

scholarly journals History of Inflammatory Bowel Diseases

2019 ◽  
Vol 8 (11) ◽  
pp. 1970 ◽  
Author(s):  
Giovanni Clemente Actis ◽  
Rinaldo Pellicano ◽  
Sharmila Fagoonee ◽  
Davide Giuseppe Ribaldone
Keyword(s):  
20Th Century ◽  
Inflammatory Bowel Diseases ◽  
Intestinal Tuberculosis ◽  
Unknown Etiology ◽  
Biological Drugs ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Novel Strategy ◽  
Definition Of ◽  
Therapeutic Research

Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal mucosa and unknown etiology. In this review, we identified three main eras in the IBD history. Between the 19th and the 20th century, the primary task had been the definition of the diagnostic criteria in order to differentiate the new entity from intestinal tuberculosis. In the 20th century, an intense and prolific therapeutic research prevailed, culminating in the introduction of biological drugs in the clinical setting. Since the beginning of the 21st century, traditional definition criteria have been challenged by holistic criteria in an effort to seek a still unattained cure. Centuries of worldwide efforts on IBD etiology and therapy search have culminated in this novel strategy.

scholarly journals Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease

2015 ◽  
Vol 2015 ◽  
pp. 1-11 ◽  
Author(s):  
Tejas Sheth ◽  
C. S. Pitchumoni ◽  
Kiron M. Das
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Multidisciplinary Approach ◽  
Physical Therapist ◽  
Cost Savings ◽  
The Past ◽  
The Us ◽  
Bowel Diseases ◽  
Musculoskeletal Manifestations ◽  
Inflammatory Bowel ◽  
Near Future

Musculoskeletal manifestations are the most common extraintestinal manifestations in inflammatory bowel diseases. Some appendicular manifestations are independent of gut inflammation and are treated with standard anti-inflammatory strategies. On the other hand, axial involvement is linked to gut inflammatory activity; hence, there is a considerable amount of treatment overlap. Biological therapies have revolutionized management of inflammatory bowel diseases as well as of associated articular manifestations. Newer mechanisms driving gut associated arthropathy have surfaced in the past decade and have enhanced our interests in novel treatment targets. Introduction of biosimilar molecules is expected in the US market in the near future and will provide an opportunity for considerable cost savings on healthcare. A multidisciplinary approach involving a gastroenterologist, rheumatologist, and physical therapist is ideal for these patients.

scholarly journals Methotrexate for Inflammatory Bowel Diseases - New Developments

2016 ◽  
Vol 34 (1-2) ◽  
pp. 140-146 ◽  
Author(s):  
Hans H. Herfarth
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Inflammatory Bowel Diseases ◽  
Antibody Formation ◽  
Clinical Effectiveness ◽  
New Developments ◽  
The Past ◽  
Steroid Dependent ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Methotrexate (MTX) is an established therapy for patients with steroid-dependent Crohn's disease (CD). MTX is also frequently used in combination with anti-TNF agents to suppress anti-drug antibody formation. It has been suggested in the past that MTX lacks any clinical effectiveness in patients with ulcerative colitis (UC); however, newer data at least partially contradict this assumption. The following review will discuss recent data for the use of MTX in CD, UC and in combination with anti-TNF agents.

Novel Diagnostic Tools to Differentiate C. Difficile Disease from Colonization in Patients with Inflammatory Bowel Diseases

2017 ◽  
Vol 152 (5) ◽  
pp. S778 ◽  
Author(s):  
Dario R. Sorrentino ◽  
Kristin Knight ◽  
Joshua G. Gazo ◽  
Vu Q. Nguyen ◽  
Lera Brannan ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Diagnostic Tools ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Bioactivity of Polyphenols: Preventive and Adjuvant Strategies toward Reducing Inflammatory Bowel Diseases—Promises, Perspectives, and Pitfalls

2016 ◽  
Vol 2016 ◽  
pp. 1-29 ◽  
Author(s):  
Anouk Kaulmann ◽  
Torsten Bohn
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Short Chain Fatty Acid ◽  
Current Knowledge ◽  
Gut Permeability ◽  
Metabolizing Enzymes ◽  
Cellular Targets ◽  
The Past ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Cytokine Formation

Inflammatory bowel diseases (IBDs) are characterized by autoimmune and inflammation-related complications of the large intestine (ulcerative colitis) and additional parts of the digestive tract (Crohn’s disease). Complications include pain, diarrhoea, chronic inflammation, and cancer. IBD prevalence has increased during the past decades, especially in Westernized countries, being as high as 1%. As prognosis is poor and medication often ineffective or causing side effects, additional preventive/adjuvant strategies are sought. A possible approach is via diets rich in protective constituents. Polyphenols, the most abundant phytochemicals, have been associated with anti-inflammatory, antioxidant, immunomodulatory, and apoptotic properties. Locally reducing oxidative stress, they can further act on cellular targets, altering gene expression related to inflammation, including NF-κB, Nrf-2, Jak/STAT, and MAPKs, suppressing downstream cytokine formation (e.g., IL-8, IL-1β, and TNF-α), and boosting the bodies’ own antioxidant status (HO-1, SOD, and GPx). Moreover, they may promote, as prebiotics, healthy microbiota (e.g., Bifidobacteria,Akkermansia), short-chain fatty acid formation, and reduced gut permeability/improved tight junction stability. However, potential adverse effects such as acting as prooxidants, or perturbations of efflux transporters and phase I/II metabolizing enzymes, with increased uptake of undesired xenobiotics, should also be considered. In this review, we summarize current knowledge around preventive and arbitrary actions of polyphenols targeting IBD.

Sign in / Sign up

Export Citation Format

Share Document